The Canadian Journal of Addiction,
Journal Year:
2024,
Volume and Issue:
15(4), P. 6 - 13
Published: Dec. 1, 2024
ABSTRACT
Since
the
original
article
was
published
over
40
years
ago,
Drug
Abuse
Screening
Test
(DAST)
developed
at
Centre
for
Addiction
and
Mental
Health—CAMH,
Toronto
(www.camh.ca/)
has
become
one
of
most
widely
used
addiction
instruments
in
North
America
internationally
population
clinical
screening,
assessment,
research
a
broad
range
settings.
The
developmental
prototype
contained
28
items
(DAST-28)
from
which
2
versions
were
derived:
10-item
DAST-10
screening
more
comprehensive
20-item
DAST-20
assessment
research.
first
aim
this
commentary
review
is
to
highlight
recent
trends
wide-ranging
use
on
DAST.
international
reach
exemplified
by
18
(currently)
translations
cultural
adaptations.
Research
shown
that
DAST
exhibits
high
levels
reliability
validity
across
public
health
settings,
it
as
benchmark
validation
studies
other
measures.
recommended
instrument
national
agencies
an
evidence-based
tool,
example,
https://cde.nida.nih.gov/.
To
address
evolving
contextual
shifts,
especially
imperative
reduce
stigma,
second
introduce
revised
designated
DAST-10-R
DAST-20-R,
incorporate
recommendations
NIDA’s
(2021)
Words
Matter—Terms
Use
Avoid
When
Talking
About
Addiction.
A
feasibility
study
described
community
center.
Future
directions
are
outlined,
including
calibration
DAST-R
with
evaluating
utilization
spectrum
health,
community,
Depuis
la
publication
de
l’article
il
y
plus
ans,
le
mis
au
point
par
Health
-
CAMH,
est
devenu
l’un
des
les
utilisés
en
Amérique
du
Nord
et
dans
monde
pour
dépistage,
l'évaluation
recherche
milieu
clinique
un
large
éventail
contextes.
Le
développement
contenait
à
partir
desquels
deux
ont
été
dérivées
:
10
dépistage
20
items,
complet,
recherche.
premier
objectif
ce
commentaire
mettre
évidence
tendances
récentes
l’utilisation
grande
échelle
La
portée
internationale
illustrée
ses
traductions
(actuelles)
adaptations
culturelles.
montré
que
présente
niveaux
élevés
fiabilité
validité
toute
une
série
contextes
cliniques
santé
publique,
qu’il
utilisé
comme
référence
études
d’autres
mesures.
recommandé
agences
nationales
tant
qu’outil
fondé
sur
données
probantes
exemple,
Pour
tenir
compte
l'évolution
contexte,
particulier
l’impératif
réduction
stigmatisation,
deuxième
présenter
révisées
désignées
qui
intègrent
recommandations
rapport
NIDA
Matter
Terms
.
Une
étude
faisabilité
centre
communautaire
décrite.
Les
orientations
futures
sont
présentées,
compris
l'étalonnage
avec
travers
spectre
communauté
environnements
cliniques.
The Lancet Public Health,
Journal Year:
2025,
Volume and Issue:
10(2), P. e148 - e159
Published: Feb. 1, 2025
SummaryCannabis
consumption
is
legally
prohibited
in
most
countries
the
world.
Several
are
legalising
cannabis
for
adult
consumption.
It
important
to
monitor
public
health
effects
of
these
policy
changes.
In
this
paper,
we
summarise
evidence
date
on
legalisation
non-medical
use
Canada
and
USA.
We
describe
regulatory
models
legalisation,
changes
products
pricing,
illicit
market,
use,
cannabis-related
physical
mental
harms.
discuss
challenges
assessing
outcomes
emphasise
importance
continuous
rigorous
monitoring
adverse
inform
design
policies
regulations.
The Lancet Regional Health - Americas,
Journal Year:
2024,
Volume and Issue:
35, P. 100773 - 100773
Published: May 17, 2024
Cannabis
is
the
most
commonly
used
non-legal
drug,
especially
among
young
people.
In
2018,
Canada
implemented
legalization
of
non-medical
cannabis
use
and
supply
for
adults.1Fischer
B.
Jutras-Aswad
D.
Hall
W.
Outcomes
associated
with
nonmedical
policy
in
Canada:
taking
stock
at
5-year
mark.CMAJ.
2023;
195:
E1351-E1353Crossref
PubMed
Scopus
(4)
Google
Scholar
This
reform
was
framed
by
multiple
primary
objectives,
which
included
improved
public
health,
safety
youth
protection,
specifically
pledging
to
"keep
out
hands
youth".
Under
formal
umbrella
('Cannabis
Act'),
may
be
legally
accessed
adults
ages
19-and-up
provinces
(with
Alberta
[18
years]
Quebec
[21
exceptions).1Fischer
While
extensive
prevention
education
campaigns
have
been
launched,
underage
criminally
charged
possession
small
(>5
g)
dried
or
equivalents.
Underage
(adolescent)
are
a
distinctly
important
vulnerable
group
cannabis-related
risks
several
reasons.
First,
Canadian
rates
traditionally
high
(e.g.,
25–45%
16–17).
Second,
adolescents,
beyond
general
substance
use-related
susceptibilities,
well-documented
elevated
risk
severe
adverse
cognitive,
mental
psycho-social)
health
outcomes
from
intensive
frequent/high-potency)
and/or
long-term
use.2Lorenzetti
V.
Hoch
E.
Adolescent
use,
cognition,
brain
educational
outcomes:
review
evidence.Eur
Neuropsychopharmacol.
2020;
36:
169-180Crossref
(69)
On
this
basis,
it
has
questioned
how
well
its
implications
would
serve
welfare
youth,
best
design
these
essential
good
interests
mind.
More
than
5-years
following
implementation
Canada,
select—while
limited—empirical
data
document
main
adolescents
socio-legal
domains.
For
key
examples,
national
Survey
(CCS),
prevalence
(in
past
12-months)
16–19
years
increased
36%
2018
43%
2023.3Government
CanadaCanadian
2023:
summary
results.https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/canadian-cannabis-survey-2023-summary.htmlDate:
2024Date
accessed:
April
7,
2024Google
Somewhat
differently,
secondary
students
(grades
7–12)
remained
steady
Student
Tobacco,
Alcohol
Drugs
(18%
both
2018/19
&
2021/22
waves)
provincial
Ontario
Drug
Use
Health
(19%
2017
17%
2021),
while
however
surveys
indicating
>30%
grades
11
12.4Centre
Addiction
Mental
(CAMH)The
well-being
-
findings
2021
student
drug
survey.https://canadacommons.ca/artifacts/2369190/the-well-being/3390205/Date
16,
Scholar,5Health
CanadaThe
Student,
2021-2022
results.https://www.canada.ca/en/health-canada/services/canadian-student-tobacco-alcohol-drugs-survey/2021-2022-summary.htmlDate
Complementary
indicate
that
initial
(2018–2019),
compared
pre-legalization
(2001–2017)
31%
likelihood
any
40%
daily
98%
dependence
students.6Imtiaz
S.
Nigatu
Y.T.
Sanches
M.
et
al.Effects
legalisation
on
patterns
consumption
Ontario,
(2001-2019).Drug
Rev.
2024;
43:
764-774Crossref
(0)
Among
under-age
(<18
years)
(<19
years),
20%
increase-equivalent
(2015–2019)
emergency
department
visits
involving
disorder/poisoning,
there
were
(moderate)
increases
psychosis,
poisoning,
withdrawal,
harmful
use)
hospitalizations
individuals
(ages
15–24)
Canada's
four
largest
provinces,
during
legalization's
'commercialization'
(2020–2021)
(2015–2018)
period.7Callaghan
R.C.
Vander
Heiden
J.
Kish
S.J.
Impact
disorders
poisoning
Alberta,
2015–2019.Drug
42:
1104-1113Crossref
(3)
Scholar,8Myran
D.T.
Gaudreault
A.
Konikoff
L.
Talarico
R.
Liccardo
Pacula
Changes
cannabis-attributable
Canada.JAMA
Netw
Open.
6e2336113https://doi.org/10.1001/jamanetworkopen.2023.36113Crossref
outcomes,
CCS
found
adolescent
users,
41%
usually
obtained
their
"legal
purchases"
legal
store/website)
"social
sources"
family/friends)
almost
none
reporting
(1%)
"illegal"
sourcing
activities
annual
driving
immediately
(i.e.
within
1
hour)
(holding
driver's
license)
majorly
declined
19.9%
2001
6.8%
2019,
no
changes
legalization.9Imtiaz
Ali
F.
al.Cannabis
under
influence
alcohol
adult
drivers
(2001–2019).Drug
Depend.
255:
111060https://doi.org/10.1016/j.drugalcdep.2023.111060Crossref
Police-enforced
offenses
(12–17
significantly
decreased
(from
32,000
2,508
male
8,971
558
female
pre-
post-legalization
(2018–2021)
periods.10Callaghan
Hathaway
Asbridge
MacDonald
police-reported
criminal
incidents
2015–2021.Drug
:
109892https://doi.org/10.1016/j.drugalcdep.2023.109892Crossref
Yet,
despite
similar
declines,
(i.e.,
use-related)
(adolescent
males:
29,015/1603;
females:
8377/367)
as
respective
relative
majorities
enforced
period.10Callaghan
Despite
supposed
'ban'
advertisement
two-thirds
(63%)
reported
exposure
advertisements
promotions
Half-a-decade
into
consequential
'normalization'
environment
cannabis,
we
observe
mixed
picture
developments
outcome
indicators
underage/adolescent
Canada.
comparably
levels,
selected
hospitalizations),
some
risk-behaviors
increased.
With
commercialization
common,
adolescents'
practices
shifted
predominantly
'illegal'
'legal'
(albeit
so
only
adults)
'grey'
'social')
sources.
Cannabis-related
enforcement
markedly
reduced;
however,
(possession)
remain
disproportionately
against
individuals,
whom
related
consequences
punishment,
record-entries,
stigma)
particularly
severe.
The—widely
promoted—objective
effective
access
reduction
particular
age
not
achieved
through
legalization.
The
results
generally
those
observed
US-based
settings.11Hammond
C.J.
Chaney
Hendrickson
Sharma
P.
U.S.
era
marijuana
legalization:
changing
patterns,
comorbidity,
correlates.Int
Rev
Psychiatry.
32:
221-234Crossref
(90)
We
infer
overall
evaluation
impact
arguably
concern
crucially
depends
variably
increasing
health-related
problems
weighted
substantive
benefit
outcomes.11Hammond
Also
observations
recent
'Cannabis
Act',
tangible
need
opportunity
adjustments
parameters
towards
better
serving
welfare.1Fischer
Scholar,12Government
CanadaLegislative
Act.
Final
report
expert
panel.https://www.canada.ca/en/health-canada/services/publications/drugs-medication/legislative-review-cannabis-act-final-report-expert-panel.html#a1Date
25,
Related
efforts
should
include
comprehensive
evidence-based
prevention)
measures
lower
continuously
(and
high-risk)
shielding
them
from—direct
indirect—access
products
fallouts
promotion/advertisement)
commercialization.
At
same
time,
categorically
recommend
criminalization
due
excessive
present
contexts.
These
insights
helpful
also
other
jurisdictions
contemplating
development
BF
developed
concept
article;
all
authors
collected
interpreted
study.
led
manuscript
writing;
DJA
TR
edited
revised
intellectual
content.
Dr.
Fischer
held
research
grants
contracts
areas
funding
government
organizations
public-only
sources)
last
five
years;
temporarily
employed
Research
Scientist
(2021–2022).
had
received
study
materials
(oral
cannabidiol
inhaled
THC)
publicly
funded
clinical
trials
examining
behavioral,
cognitive
biological
effects
cannabinoids.
He
employed,
owned
stocks
nor
honoraria
payments
Cardiol
Therapeutics
Exka.
Mrs.
Robinson
competing
declare.
Funding:
acknowledges
fellowship
Max-Planck-Society,
Germany.
scientist
career
award
Fonds
de
Recherche
du
Québec
(FRQS).
supported
specific
sponsor
funder.
Kinder- und Jugendmedizin,
Journal Year:
2025,
Volume and Issue:
25(01), P. 50 - 57
Published: Feb. 1, 2025
Zusammenfassung
Cannabis
gehört
zu
den
am
häufigsten
von
Jugendlichen
konsumierten
Suchtmitteln.
Vor
dem
Hintergrund
der
kürzlich
in
Deutschland
erfolgten
Cannabislegalisierung
ist
auch
zukünftig
einer
hohen
klinischen
Relevanz
bei
Kindern
und
auszugehen.
In
dieser
Übersichtsarbeit
werden
die
Grundlagen
Aspekte
des
Cannabiskonsums
sowie
damit
verbundenen
psychischen
Störungen
vorgestellt.
Der
Übergang
vom
Jugend-
zum
Erwachsenenalter
geht
mit
neurobiologischen
Prozessen
einher,
junge
Cannabis-Konsumenten
besonders
anfällig
für
Entwicklung
Abhängigkeit
anderer
psychischer
machen.
Diagnostik
Therapie
Cannabisabhängigkeit
-missbrauch
unter
Berücksichtigung
Besonderheiten
minderjährigen
Personen
erörtert
anhand
Kasuistiken
veranschaulicht.
Indian Journal of Psychiatry,
Journal Year:
2025,
Volume and Issue:
67(3), P. 283 - 302
Published: March 1, 2025
Background:
Cannabis
has
been
associated
with
psychopathology
since
ancient
times,
but
controversies
continue
despite
important
advances
in
the
field.
This
article
is
fourth
one
our
decadal
series
of
review
articles
that
have
providing
an
update
snapshot
meandering
journey
research
findings
this
area.
Aims:
narrative
a
comprehensive
literature
search
over
past
10
years
aims
to
provide
and
current
understanding,
while
raising
unanswered
questions
for
future,
focusing
on
following
areas:
(a)
nosological
changes
cannabis-related
psychiatric
syndromes;
(b)
newer
category
synthetic
cannabinoids;
(c)
cannabis
withdrawal
syndrome);
(d)
psychosis;
(e)
mood
disorders;
(f)
suicidality;
(g)
prenatal
use
offspring;
(h)
effect
recent
liberal
policy
overhaul
control
certain
countries/areas
adverse
outcomes;
(i)
cognition;
(j)
cannabis,
psychopathology,
genetics.
Methods:
The
data
strategies
involved
combination
electronic
databases
manual
hand-searching
relevant
publications
cross-references
using
selected
terms.
primary
focused
Medline
PubMed
Central
extended
such
as
Google
Scholar,
PsychINFO,
Scopus,
Ovid
specific
sections.
Key
references
identified
through
searches
provided
additional
material.
Inclusion
criteria
spanned
studies
published
between
January
2014
June
2024,
more
emphasis
placed
(post-2020)
ensuring
historical
coverage.
Results:
aimed
be
comprehensive,
including
broad
range
without
strict
methodological
exclusions.
Strengths
limitations
cited
are
discussed
when
applicable,
maintaining
consistency
three
prior
reviews.
We
syndromes,
human
(rather
than
animal)
studies,
applied
basic)
research.
only
reference
not
entire
area
because
would
beyond
scope
article.
There
updates
all
areas
covered.
syndromal
entities
ICD-11,
which
also
includes
cannabinoids
first
time.
syndrome
better
characterized.
association
psychosis
robustly
established
especially
very
high-potency
vulnerable
populations,
particularly
young
people.
Work
progress
elucidating
causal
mechanisms.
links
disorders
well
suicidality
cognitive
impairment
characterized,
though
remain.
Recent
liberalizing
policies
produced
accidental
(with
deleterious
effects
offspring)
later
(mixed
findings,
documented
increase
emergency
visits
related
use).
will
require
active
monitoring
new
data.
Conclusion:
field
continues
collect
settle
some
old
questions,
address
view
wide
worldwide
its
implications
public
health.
BMC Oral Health,
Journal Year:
2025,
Volume and Issue:
25(1)
Published: April 29, 2025
Two-Spirit,
lesbian,
gay,
bisexual,
transgender,
queer
or
questioning,
intersex,
other
sexual
orientations
and
gender
identities
(2SLGBTQI+)
youth
face
multiple
social
structural
disparities
barriers
that
contribute
to
a
sense
of
mistrust
in
the
provision
healthcare
services,
including
oral
health.
Cannabis
use
is
also
high
among
2SLGBTQI+
individuals;
however,
unknowns
exist
regarding
recreational
its
impact
on
Our
research
aims
explore
intersectionality
youth,
health,
cannabis
consumption.
This
qualitative
study,
guided
by
community-based
participatory
interpretative
phenomenological
approaches,
will
recruit
consenting
aged
19
older,
accessing
services
at
Youth
Opportunities
Unlimited
London,
Canada.
Approximately
25
30
participants
be
recruited
complete
one-on-one
in-depth
interview
focus
group
collect
information
their
perception
about
relationships
between
Recognizing
self-perceived
pathways
through
which
impacts
health
prompt
development
theories,
raise
awareness,
support
advocacy
efforts
for
while
providing
valuable
insights
community
providers
large.
Drugs Education Prevention and Policy,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 7
Published: April 5, 2024
Background:
Cannabis
legalization
policy
is
increasingly
implemented
to
improve
public
health
and
safety
outcomes,
including
in
Canada
(since
2018).
Main
outcome
assessments
have
primarily
focused
on
categorical
(e.g.
pre-/post-)
reform
effects,
while
differential
regulation
frameworks
been
less
considered.
For
this,
provides
a
rich
ecology
where
provinces
diversely
define
many
parameters
under
the
federal
umbrella,
with
Alberta
Quebec
as
respectively
least
most
tightly
regulated
provincial
units.Methods:
Based
basic,
targeted
search,
we
identified
summarized
key
publicly
available,
cross-sectional
indicator
data
for
primary
socio-legal
post-legalization
outcomes
Quebec.Results:
Data
suggested
substantial
inter-provincial
differences
cannabis
use
among
adults
youth)
legal
sourcing
levels,
select
use-related
risks/harm
cannabis-impaired
driving,
cannabis-related
motor-vehicle-crashes).
Other
specific
poisonings,
home-cultivation)
showed
that
may
plausibly
relate
distinct
frameworks.Discussion:
While
possible
ecological
or
independent
effects
exist,
exploratory
suggest
different
regulatory
influence
legalization-related
and/or
outcomes.
Related
differentials
should
be
systematically
examined
causal
associations
regulations
towards
informing
evidence-based
development.